Brief

"On March 14, 2025, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding Worsening of tensions in pegasys: new measurements and updated repository. The agency introduced a strict protocol to ensure patients without alternative therapies access treatment with peginterferon alfa-2a, while restricting its use for certain indications and co-infections due to stock limitations."

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies